Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH

The New England journal of medicine22 Jun 2025Cited by 149 (Europe PMC)

PMID40544433DOI10.1056/nejmoa2502081PepBankPUB-40544433

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, cagrilintide-semaglutide reduced body weight from baseline to week 68 by 20.4% versus 3.0% with placebo.
In plain wordsIn adults with overweight or obesity, cagrilintide with semaglutide cut body weight by 20.4% over 68 weeks, compared with 3.0% with placebo.
Peptide
Cagrilintide
Outcome
DecreaseRelative change in body weight at week 68
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Mean percent change in body weight
−20.4%
cagrilintide-semaglutide
Mean percent change in body weight
−3%
placebo
Estimated difference
−17.3 percentage points
cagrilintide-semaglutide vs placebo
Source sentences
Summary
The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443301
02HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, more participants on cagrilintide-semaglutide than on placebo reached a weight reduction of 5% or more at week 68.
In plain wordsIn adults with overweight or obesity, more people on cagrilintide with semaglutide lost 5% or more of body weight than on placebo.
Peptide
Cagrilintide
Outcome
IncreaseWeight reduction of 5% or more
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443302
03HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, cagrilintide-semaglutide (CagriSema) lowered body weight by 20.4% versus 3.0% with placebo at week 68.
In plain wordsIn adults with overweight or obesity, the CagriSema combination reduced body weight much more than placebo over 68 weeks.
Peptide
Semaglutide
Outcome
DecreaseBody weight percent change at week 68
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
body weight change
−20.4%
cagrilintide-semaglutide
body weight change
−3%
placebo
estimated difference
−17.3 percentage points
cagrilintide-semaglutide versus placebo
Source sentences
Summary
The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443307
04HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, more patients on CagriSema than on placebo reached a weight reduction of 5% or more.
In plain wordsIn adults with overweight or obesity, more people on the CagriSema combination than on placebo lost at least 5% of body weight.
Peptide
Semaglutide
Outcome
IncreaseWeight reduction of at least 5%
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443308
05HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, more participants on cagrilintide-semaglutide than on placebo reached a weight reduction of 20% or more.
In plain wordsIn adults with overweight or obesity, more people on cagrilintide with semaglutide lost 20% or more of body weight than on placebo.
Peptide
Cagrilintide
Outcome
IncreaseWeight reduction of 20% or more
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443303
06HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, more participants on cagrilintide-semaglutide than on placebo reached a weight reduction of 25% or more.
In plain wordsIn adults with overweight or obesity, more people on cagrilintide with semaglutide lost 25% or more of body weight than on placebo.
Peptide
Cagrilintide
Outcome
IncreaseWeight reduction of 25% or more
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443304
07HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity, more participants on cagrilintide-semaglutide than on placebo reached a weight reduction of 30% or more.
In plain wordsIn adults with overweight or obesity, more people on cagrilintide with semaglutide lost 30% or more of body weight than on placebo.
Peptide
Cagrilintide
Outcome
IncreaseWeight reduction of 30% or more
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443305
08HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, more patients on CagriSema than on placebo reached a weight reduction of 20% or more.
In plain wordsIn adults with overweight or obesity, more people on the CagriSema combination than on placebo lost at least 20% of body weight.
Peptide
Semaglutide
Outcome
IncreaseWeight reduction of at least 20%
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443309
09HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, more patients on CagriSema than on placebo reached a weight reduction of 25% or more.
In plain wordsIn adults with overweight or obesity, more people on the CagriSema combination than on placebo lost at least 25% of body weight.
Peptide
Semaglutide
Outcome
IncreaseWeight reduction of at least 25%
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443310
10HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity without diabetes, more patients on CagriSema than on placebo reached a weight reduction of 30% or more.
In plain wordsIn adults with overweight or obesity, more people on the CagriSema combination than on placebo lost at least 30% of body weight.
Peptide
Semaglutide
Outcome
IncreaseWeight reduction of at least 30%
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443311
11HumanNot a test of Cagrilintide aloneRandomized controlled trialSafety outcome
In adults with overweight or obesity, gastrointestinal adverse events affected 79.6% on cagrilintide-semaglutide versus 39.9% on placebo, mainly transient and mild-to-moderate.
In plain wordsIn adults with overweight or obesity, stomach and bowel side effects were more common with cagrilintide plus semaglutide than with placebo, mostly mild.
Peptide
Cagrilintide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Gastrointestinal adverse events
79.6%
cagrilintide-semaglutide
Gastrointestinal adverse events
39.9%
placebo
Source sentences
Summary
Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443306
12HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome
In adults with overweight or obesity without diabetes, gastrointestinal adverse events affected 79.6% on CagriSema versus 39.9% on placebo, mainly transient and mild-to-moderate.
In plain wordsIn adults with overweight or obesity, stomach and gut side effects were more common with the CagriSema combination than with placebo.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
GI adverse events
79.6%
cagrilintide-semaglutide
GI adverse events
39.9%
placebo
Source sentences
Summary
Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obe…
Summary · context
Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443312

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 3NCT05567796

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Novo Nordisk A/Sn = 3,4001 Nov 2022 to est. 19 Oct 2026

Obesity

Trial page ClinicalTrials.govUpdated 30 Sept 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC